Personalized Therapy for Prostate Cancer Due to Genetic Testings

Stephen J. Freedland, MD, is a Professor of Surgery and holds the Warschaw Robertson Law Families Chair in Prostate Cancer at Cedars-Sinai Medical Center in Los Angeles. He is also Director of the Center for Integrated Research in Cancer and Lifestyle, Co-Director of the Cancer Genetics and Prevention Program, and Associate Director of the Faculty Development Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. Freedland is an expert on urological diseases, particularly benign prostatic hyperplasia and prostate cancer. He is interested in combining Western and holistic medicine for cancer treatment and prevention. His other research interests include urological diseases and the role of diet, lifestyle, and obesity in prostate cancer development and progression, as well as prostate cancer among racial groups and risk stratification for men with prostate cancer. Freedland has published over 400 studies in peer-reviewed journals. He is also a reviewer for more than 50 journals. He is on the editorial board for Cancer Prevention Research, European Urology, the International Journal of Urology, Nature Reviews Urology, and BJUI, and serves as Editor-in-Chief for Prostate Cancer and Prostatic Diseases and as a consulting editor for European Urology. Dr. Freedland earned his MD from the University of California, Davis. He completed a Residency in Urology at UCLA and a Fellowship in Urological Oncology at Johns Hopkins. Before joining Cedars-Sinai, he served as an Associate Professor of Urology at Duke University.